Cargando…
1647. Clinical Outcomes in Pediatric Appendectomy Patients Treated with Piperacillin-Tazobactam versus Ceftriaxone/Metronidazole
BACKGROUND: Appendicitis is the most common cause of emergent pediatric surgeries. The standard treatment includes surgical removal of the appendix plus or minus antibiotic therapy. Piperacillin-tazobactam or ceftriaxone/metronidazole are commonly utilized antibiotic regimens. While the latter optio...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10678379/ http://dx.doi.org/10.1093/ofid/ofad500.1481 |
_version_ | 1785150347515265024 |
---|---|
author | Cosimi, Reese Daragjati, Florian Ward, Sasha Whitmore, Maria Marisol, Fernandez Moreno, Ana Cristina Perez Miller, Collin Fakih, Mohamad G |
author_facet | Cosimi, Reese Daragjati, Florian Ward, Sasha Whitmore, Maria Marisol, Fernandez Moreno, Ana Cristina Perez Miller, Collin Fakih, Mohamad G |
author_sort | Cosimi, Reese |
collection | PubMed |
description | BACKGROUND: Appendicitis is the most common cause of emergent pediatric surgeries. The standard treatment includes surgical removal of the appendix plus or minus antibiotic therapy. Piperacillin-tazobactam or ceftriaxone/metronidazole are commonly utilized antibiotic regimens. While the latter option may be preferable for antimicrobial stewardship measures due to its narrower spectrum of activity, current existing evidence is conflicting as to whether one results in improved clinical outcomes. METHODS: Retrospective cohort study across four regionally diverse pediatric hospitals of all admitted patients aged 0 to 17 years with a procedure code for appendix resection between January 1, 2021 to December 31, 2022. Patients were included if they received either piperacillin-tazobactam or ceftriaxone/metronidazole during the encounter corresponding to the appendectomy procedure. Outcomes measured include length-of-stay (LOS) and 30-day readmission. RESULTS: A total of 600 appendectomy cases were included in the analysis of which 463 received ceftriaxone/metronidazole and 137 patients received piperacillin-tazobactam. Patients aged < 10 years old were more likely to receive piperacillin-tazobactam. More perforated appendicitis cases were noted in the patients who received ceftriaxone/metronidazole. Average LOS in days (standard deviation) was not different between the two groups, 4.2 (6.1) and 3.9 (6.3), respectively (p=0.25). Readmissions were more common in the patients who received piperacillin-tazobactam, 3.2% and 7.3% (p=0.04). [Figure: see text] CONCLUSION: Clinical outcomes in pediatric appendectomy patients do not appear to be associated with antibiotic regimen selection. Our study supports the continued use of ceftriaxone/metronidazole first line for appendicitis treatment in children taking into account local susceptibility patterns. DISCLOSURES: Reese Cosimi, PharmD, Allergen: Advisor/Consultant |
format | Online Article Text |
id | pubmed-10678379 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | Oxford University Press |
record_format | MEDLINE/PubMed |
spelling | pubmed-106783792023-11-27 1647. Clinical Outcomes in Pediatric Appendectomy Patients Treated with Piperacillin-Tazobactam versus Ceftriaxone/Metronidazole Cosimi, Reese Daragjati, Florian Ward, Sasha Whitmore, Maria Marisol, Fernandez Moreno, Ana Cristina Perez Miller, Collin Fakih, Mohamad G Open Forum Infect Dis Abstract BACKGROUND: Appendicitis is the most common cause of emergent pediatric surgeries. The standard treatment includes surgical removal of the appendix plus or minus antibiotic therapy. Piperacillin-tazobactam or ceftriaxone/metronidazole are commonly utilized antibiotic regimens. While the latter option may be preferable for antimicrobial stewardship measures due to its narrower spectrum of activity, current existing evidence is conflicting as to whether one results in improved clinical outcomes. METHODS: Retrospective cohort study across four regionally diverse pediatric hospitals of all admitted patients aged 0 to 17 years with a procedure code for appendix resection between January 1, 2021 to December 31, 2022. Patients were included if they received either piperacillin-tazobactam or ceftriaxone/metronidazole during the encounter corresponding to the appendectomy procedure. Outcomes measured include length-of-stay (LOS) and 30-day readmission. RESULTS: A total of 600 appendectomy cases were included in the analysis of which 463 received ceftriaxone/metronidazole and 137 patients received piperacillin-tazobactam. Patients aged < 10 years old were more likely to receive piperacillin-tazobactam. More perforated appendicitis cases were noted in the patients who received ceftriaxone/metronidazole. Average LOS in days (standard deviation) was not different between the two groups, 4.2 (6.1) and 3.9 (6.3), respectively (p=0.25). Readmissions were more common in the patients who received piperacillin-tazobactam, 3.2% and 7.3% (p=0.04). [Figure: see text] CONCLUSION: Clinical outcomes in pediatric appendectomy patients do not appear to be associated with antibiotic regimen selection. Our study supports the continued use of ceftriaxone/metronidazole first line for appendicitis treatment in children taking into account local susceptibility patterns. DISCLOSURES: Reese Cosimi, PharmD, Allergen: Advisor/Consultant Oxford University Press 2023-11-27 /pmc/articles/PMC10678379/ http://dx.doi.org/10.1093/ofid/ofad500.1481 Text en © The Author(s) 2023. Published by Oxford University Press on behalf of Infectious Diseases Society of America. https://creativecommons.org/licenses/by/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/), which permits unrestricted reuse, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Abstract Cosimi, Reese Daragjati, Florian Ward, Sasha Whitmore, Maria Marisol, Fernandez Moreno, Ana Cristina Perez Miller, Collin Fakih, Mohamad G 1647. Clinical Outcomes in Pediatric Appendectomy Patients Treated with Piperacillin-Tazobactam versus Ceftriaxone/Metronidazole |
title | 1647. Clinical Outcomes in Pediatric Appendectomy Patients Treated with Piperacillin-Tazobactam versus Ceftriaxone/Metronidazole |
title_full | 1647. Clinical Outcomes in Pediatric Appendectomy Patients Treated with Piperacillin-Tazobactam versus Ceftriaxone/Metronidazole |
title_fullStr | 1647. Clinical Outcomes in Pediatric Appendectomy Patients Treated with Piperacillin-Tazobactam versus Ceftriaxone/Metronidazole |
title_full_unstemmed | 1647. Clinical Outcomes in Pediatric Appendectomy Patients Treated with Piperacillin-Tazobactam versus Ceftriaxone/Metronidazole |
title_short | 1647. Clinical Outcomes in Pediatric Appendectomy Patients Treated with Piperacillin-Tazobactam versus Ceftriaxone/Metronidazole |
title_sort | 1647. clinical outcomes in pediatric appendectomy patients treated with piperacillin-tazobactam versus ceftriaxone/metronidazole |
topic | Abstract |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10678379/ http://dx.doi.org/10.1093/ofid/ofad500.1481 |
work_keys_str_mv | AT cosimireese 1647clinicaloutcomesinpediatricappendectomypatientstreatedwithpiperacillintazobactamversusceftriaxonemetronidazole AT daragjatiflorian 1647clinicaloutcomesinpediatricappendectomypatientstreatedwithpiperacillintazobactamversusceftriaxonemetronidazole AT wardsasha 1647clinicaloutcomesinpediatricappendectomypatientstreatedwithpiperacillintazobactamversusceftriaxonemetronidazole AT whitmoremaria 1647clinicaloutcomesinpediatricappendectomypatientstreatedwithpiperacillintazobactamversusceftriaxonemetronidazole AT marisolfernandez 1647clinicaloutcomesinpediatricappendectomypatientstreatedwithpiperacillintazobactamversusceftriaxonemetronidazole AT morenoanacristinaperez 1647clinicaloutcomesinpediatricappendectomypatientstreatedwithpiperacillintazobactamversusceftriaxonemetronidazole AT millercollin 1647clinicaloutcomesinpediatricappendectomypatientstreatedwithpiperacillintazobactamversusceftriaxonemetronidazole AT fakihmohamadg 1647clinicaloutcomesinpediatricappendectomypatientstreatedwithpiperacillintazobactamversusceftriaxonemetronidazole |